Showing 3021-3030 of 6035 results for "".
- Expert: Hospitals Should Prepare For Pent-Up Demand From Non-COVID-19 Patientshttps://modernod.com/news/expert-hospitals-should-prepare-for-pent-up-demand-from-non-covid-19-patients/2477848/While much of the focus has been on “flattening the curve” when it comes to COVID-19, experts warn hospitals should be prepared for another potential surge: pent-up demand for deferred care, according to a FierceHealthcare
- Port Delivery System With Ranibizumab Shows Positive Phase 3 Results in Wet AMDhttps://modernod.com/news/port-delivery-system-with-ranibizumab-shows-positive-phase-3-results-in-wet-amd/2477824/Genentech announced positive topline results from the phase 3 Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with wet age-related macular degeneration (AMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continu
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus
- CooperVision Biofinity Toric Multifocal Contact Lenses Now Available Nationwide in the UShttps://modernod.com/news/coopervision-biofinity-toric-multifocal-contact-lenses-now-available-nationwide-in-the-us/2477786/CooperVision has announced that its new Biofinity toric multifocal contact lenses are now available nationwide in the United States. “Amid the COVID-19 pandemic, we understand that eye care practices are operating under various circumstances, and for many, fitting contact lenses still may
- EyePoint Pharmaceuticals Presents Data Showcasing Dexycu at the ASCRS Virtual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-presents-data-showcasing-dexycu-at-the-ascrs-virtual-meeting/2477784/EyePoint Pharmaceuticals announced the presentation of positive retrospective case study data supporting Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery. The data were presented in three electronic posters and one oral pape
- VSY Biotechnology Says It Has Developed a New Drug to Treat COVID-19https://modernod.com/news/vsy-biotechnology-says-it-has-developed-a-new-drug-to-treat-covid-19/2477774/Ophthalmic company VSY Biotechnology announced that its research center has developed a new drug, TR-C 19, to treat COVID-19. Studies have shown that TR-C 19 can neutralize the virus isolated under laboratory conditions, according to a company news release. The drug is now at the authority
- Artificial Intelligence Algorithm Can Rapidly Detect Severity of Common Blinding Eye Diseasehttps://modernod.com/news/artificial-intelligence-algorithm-can-rapidly-detect-severity-of-common-blinding-eye-disease/2477752/A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), according to a company news release. The study, published in the April/May issue of Tr
- VisionCare Announces CE Mark Approval of the Tsert-SI Delivery System for the CentraSight Treatment Programhttps://modernod.com/news/visioncare-announces-ce-mark-approval-of-the-tsert-si-delivery-system-for-the-centrasight-treatment-program/2477744/VisionCare has received CE Mark for the Tsert-SI delivery system for the CentraSight treatment program, which includes the Implantable Miniature Telescope (by Dr. Isaac Lipshitz). The Tsert-SI delivery system includes a pre-loaded telescope implant injector, which only requires a 6.5mm incision,
- Dyno Therapeutics Collaborates With Novartis to Develop Improved Gene Therapies With AAV Vectors Based on AI Technologyhttps://modernod.com/news/dyno-therapeutics-collaborates-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology/2477740/Dyno Therapeutics announced a collaboration with Novartis to develop improved adeno-associated virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. Financial terms of the deal were not disclosed. The partnership will allow the p
- Visual Impairment Tied to Increased Dementia Risk in Older Womenhttps://modernod.com/news/visual-impairment-tied-to-increased-dementia-risk-in-older-women/2477730/Older women with objective visual impairment are likely to develop dementia or mild cognitive impairment, a secondary analysis of data from the Women’s Health Initiative (WHI) suggests, according to a Reuters report. Researche